Monday, October 15, 2012

Sandoz strengthens leadership in generic dermatology with launch of generic version of TOPICORT® 0.25% Ointment

Sandoz has received USFDA approval for desoximetasone ointment USP, 0.25%, a generic equivalent of leading dermatology medicine TOPICORT® 0.25% Ointment. Desoximetasone ointment is a topical corticosteroid used to relieve redness, swelling,
and itching that result from various inflammatory skin diseases.  Desoximetasone ointment is the first Fougera dermatology product Sandoz has launched since its acquisition of Fougera Pharmaceuticals.
According to IMS Health, US sales for branded and generic versions of desoximetasone ointment were 36.5 million for the 12 months ending in August 2012. Sandoz is marketing desoximetasone ointment in the 0.25% strength, the same strength that is marketed as TOPICORT® 0.25% Ointment.

Source - Sandoz Press Release